20 articles
A pilot study finds one 30-minute PAPIMI electromagnetic field session significantly reduced pain scores and raised parasympathetic HRV markers in chronic musculoskeletal pain patients.
Phase 1 trial examines whether vesatolimod can safely stimulate immune response in HIV controllers during treatment interruption.
Scientists discover tumor-associated immune cells can promote nerve growth and dramatically improve spinal cord injury recovery.
New research reveals efgartigimod reshapes B-cell populations in myasthenia gravis, inducing regulatory plasma cells linked to clinical improvement.
A Stanford RCT finds pulsed electromagnetic field therapy significantly reduces thumb CMC osteoarthritis pain at 6 weeks, even after treatment ends.
Revolutionary cell therapy achieves drug-free remission in patients with severe myasthenia gravis, an autoimmune muscle disorder.
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
Researchers repurpose mRNA-lipid nanoparticle technology to prevent and treat allergic asthma in mice, achieving ~100-fold reduction in airway eosinophils.
New antigen-specific tolerance approach could treat multiple sclerosis and related diseases without broad immunosuppression.
A Phase 1 pilot trial explores whether the IL-12/23 blocker ustekinumab is safe and can reduce systemic inflammation in Sjögren's patients.
Stanford researchers used modified immune proteins to enhance neurogenesis and cognitive function in aged mouse brains.
Revolutionary nasal spray vaccine protects against multiple respiratory threats for months by supercharging lung immunity.
A rigorous Cochrane protocol sets the stage to evaluate whether vitrectomy surgery outperforms drug therapy alone for non-infectious uveitis.
Researchers develop standardized lung washing procedure that rapidly improves breathing and quality of life in patients with rare disease.
Scientists develop potent α5β1 integrin inhibitor for inhalation therapy, offering new approach for severe asthma patients.
65 neurologists from 54 Italian MS centers agree on when and how to use high-efficacy therapies to prevent irreversible disability.
A Phase 3 trial compares neutralizing antibody responses from inactivated-virus vaccine VLA2001 vs. AZD1222, plus a dedicated adolescent arm.
New research shows how targeted interleukin-2 treatment can restore regulatory T cells and reduce muscle inflammation in autoimmune conditions.
A mechanistic deep-dive into cutting-edge anti-inflammaging interventions — from senolytic pharmacology and precision cytokine targeting to partial reprogramming strategies that aim to restore youthful immune homeostasis.
